MedTrace Logo

Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis

NCT03288584 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2020-04-03

No results posted yet for this study

Summary

Recent studies show beneficial effect of the inhibition of interleukin-6 (IL-6) activity on vascular and left ventricular (LV) function. The purpose of this study is to investigate whether anakinra, an IL-6 receptor antagonist, improves vascular, endothelial and LV function in patients with rheumatoid arthritis (RA).

Conditions

Interventions

DRUG

Tocilizumab (Actemra®)

Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection

DRUG

Other biological agent

Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)

DRUG

Corticosteroid and non-biological agents.

Enhanced treatment with corticosteroid and non-biological agents.

Sponsors & Collaborators

  • University of Athens

    lead OTHER

Principal Investigators

  • Ignatios Ikonomidis, MD · National and Kapodistrain University of Athens

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-27
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03288584 on ClinicalTrials.gov